Breast cancer is the leading cause of cancer-related death for women, and multidrug resistance (MDR) is the major obstacle faced by chemotherapy for breast cancer. We have previously synthesized a doxorubicin (DOX) derivative by conjugating DOX with triphenylphosphonium (TPP) to achieve mitochondrial delivery, which induced higher cytotoxicity in drug-resistant breast cancer cells DOX). The product was analyzed uisng 1 H-NMR, 13 C-NMR and mass spectrometry. The HA nanocarriers (HA-ionic-TPP-DOX) were shown to self-assemble into spherical nanoparticles, and sensitive to acidic pH in terms of morphology and drug release. Compared with free DOX, HA-ionic-TPP-DOX produced much greater intracellular DOX accumulation and mitochondrial localization, leading to increased ROS production, slightly decreased mitochondrial membrane potential, increased cytotoxicity in MCF-7/ADR cells and enhanced tumor targeting in vivo favorable biocompatibility and anti-tumor effects in MCF-7/ADR tumor-bearing nude mice in comparison with the effects of TPP-DOX and DOX, suggesting the potential of HA-ionic-TPP-DOX for the targeted delivery and controlled release of TPP-DOX, which can lead to the sensitization of resistant breast tumors.
Introduction
Breast cancer is the most common type of cancer in women around the world, and chemotherapy is the major form of -motherapy are hampered by multidrug resistance (MDR). Several mechanisms may be involved in MDR, including the overexpression of efflux pumps such as P-glycoprotein (P-gp) [1] , decreased drug uptake, altered intracellular drug localization, enhanced repair of drug-induced DNA damage and hindered apoptotic pathways [2] . To overcome the drug resistance of cancer, many approaches have been reported. In this context, perhaps the transporters, an important mechanism for the resistance of breast cancer cells to common chemotherapy agents, such as doxorubicin and paclitaxel. Various nano-carriers have been developed to overcome efflux-mediated resistance either by evading the interaction of chemotherapeutic drugs with transporters or by co-delivering inhibitors of drug efflux pumps to tumors along with anti-cancer drugs. Some nano-carriers could simultaneously deliver genes [3] that affect cellular MDR pathways, such as siBcl-2 [4, 5] , siP-gp [6, 7] , and sisurvivin [8] . Many chemotherapy drugs have targeted particular subcellular compartments. The accessibility of these subcellular drug targets to DOX may become limited in MDR cells. For example, the action of DOX in the cell nucleus leads to DNA damage by inhibiting topoisomerase enzymes [9] . However, MDR tumor cells will discharge DOX from the cell nucleus and minimize its access to topoisomerase enzymes. Mitochondria are another subcellular target of DOX. Mitochondria are essential intracellular organelles that ensure cell survival and regulate cell apoptosis [10, 11] . Research has revealed a relationship between mitochondrial dysfunction and diseases such as cancer, Alzheimer's [12] , diabetes [13] , ischemia-reperfusion injury and many more. The delivery of chemotherapy drugs to the mitochondria can be achieved by taking advantage of the high membrane potential [14] and protein import machinery or the mitochondria targeting sequence (MTS) [15, 16] . It has been reported that lipophilic cations [17] can readily cross mitochondrial membranes and accumulate within mitochondria. Triphenylphosphonium (TPP) [18, 19] has commonly been used for this purpose. For instance, TPP has been used to modify the surface of paclitaxel liposomes [20] and to create triphenylphosphine-chitosan-graft-PEI-lonidamine/siRNA/poly(acrylic acid)-polyethylene glycol-folic acid nanoparticles [21] , CoQ10/ poly(ethylene glycol)-polycaprolactone-triphenylphosphonium bromide micelles [22] , and G4-PAMAM-poly(ethylene glycol)-triphenylphosphonium [23] . However, the surface charges of nanoparticles that were modified by TPP were shown to be positive, resulting in off-target in vivo effects. In addition, the large particle size of these nanoparticles is disadvantageous for intracellular mitochondria targeting [24] . Previously, we have reported on the development of a small molecular mitochondriotropic doxorubicin derivative (TPP-DOX [25] ). To form that derivative, TPP is directly conjugated to DOX by an amide bond to achieve mitochondrial targeting. the toxicity of DOX to MDA-MB-435/DOX-resistant cancer cells. In this study, we linked TPP-DOX to water-soluble HA by an ionic bond to form supra-molecular self-assembled structures ( Figure 1) . Meanwhile, an MCF-7/ADR-(CM-Dil) in vivo anti-tumor activity of the HA-ionic-TPP-DOX due to the [26, 27] .
Materials and methods
Materials MCF-7/ADR cells were purchased from Nanjing KeyGen Biotech Co, Ltd (Nanjing, China). N-hydroxysuccinimide (NHS), N,N triphenylphosphonium bromide (TPP) were purchased from Sigma-Aldrich (St Louis, MO, USA). Silver nitrate was purchased from Aladdin (China). Doxorubicin hydrochlorid was obtained from Zhejiang Provincial People's Hospital (Zhejiang, China). Sodium salt hyaluronic acid (HA, Mw 48 kDa) was purchased from Zhengda Freda Co (Ji-nan, China). All other chemicals were of analytical grade.
Synthesis of TPP-DOX
The synthesis of TPP-DOX was carried out as described previously [25] . Briefly, TPP (9.3 mmol), DCC (12 mmol) and NHS (12 mmol) were dissolved in DMF (10 mL). The reaction mixture was stirred with a magnetic stirrer at room temperature for 3 h. Triethylamine (9.3 mmol) was added to a solution of DOX (9.3 mmol) in DMF (10 mL) and stirred for 0.5 h to alkalify DOX. Subsequently, the alkaline DOX solution was added dropwise to the activated TPP solution. This reaction was carried out at 0 °C for 45 min and then at room temperature overnight. The crude product was obtained by precipitation with a large amount of diethyl ether. The precipitate was dissolved in trichloromethane. After evaporation, it was extracted with deionized water to remove impurities. Finally, the product was purified on a silica gel plate (CHCl 3 /MeOH=4/1, 0.5% triethylamine).
Preparation of HA-ionic-TPP-DOX TPP-DOX was conjugated to HA by using silver nitrate as an activating reagent. HA (35 mg) and silver nitrate (8 mg) were dissolved in distilled water (10 mL) with the pH adjusted to 7.5 and then reacted for 2 h to form HA-(COO -Ag + ). After free Ag + was removed from HA-(COO -Ag + ) by dialysis against water, 10 mL of TPP-DOX solution (4 mg/mL) was added to the HA-(COO -Ag + ) solution dropwise. HA-ionic-TPP-DOX was obtained after insoluble silver bromide formed by the reaction between bromide ion in TPP-DOX and Ag + in HA-(COO -Ag + ) was removed by high-speed centrifugation (15 000 r/min, 10 min). After the reaction proceeded with stirring overnight, the solution was poured into a dialysis bag (MWCO 8000-14000) and dialyzed against a large excess amount of deionized water to remove impurities, and then, the product in the dialysis bag was collected.
The product was analyzed by mass spectrometry (Agilent 1290 HPLC-6224 Time-of-Flight Mass Spectrometer) Particle size and transmission electron microscopy (TEM) The particle size and zeta potential were measured by using a Zetasizer Nano-S90 (Malvern Instruments, Ltd, UK). To investigate the role of TPP-DOX in the self-assembly behavior of HA-ionic-TPP-DOX, the morphologies of HA-ionic-TPP-DOX were observed by transmission electron microscopy (JEM1200EX, Japan) after dialysis against excess PBS (pH 4.0) to remove TPP-DOX.
In vitro release studies
Release experiments were performed at pH 7.4 and pH 5.0. For each release study, 0.2 mg of HA-ionic-TPP-DOX was added to 1 mL of H 2 O, and the solution was placed in a dialysis tube (MWCO: 8000-14000 Da). Then, the dialysis tube was immersed directly in 25 mL of 0.2 mol/L phosphate buffer solution (pH=7.4 or 5.0) and shaken at 37 °C in a thermostatic oscillator. The concentration of the released TPP-DOX from HA-ionic -cence intensity at 570 nm in reference to the standard calibration curve.
Cell culture MCF-7/ADR cells were cultured in RPMI-1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum (Gibco Life Technologies Co., Carlsbad, USA ) at 37 °C in a humidified 5% CO 2 incubator (HF151UV, Heal Force, HK).
Uptake of and DOX MCF-7/ADR cells were seeded into 6-well plates at a density of 10 6 cells/well. After 24 h, the cells were incubated with free DOX solution, TPP-DOX or HA-ionic-TPP-DOX in RPMI-1640 medium for 1 h at equivalent DOX concentrations (8.6 and 17.2 analysis (FC500MCL, Beckman Coulter, USA) to determine DOX uptake.
Cytotoxicity assay in vitro
The in vitro cytotoxicity was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, MCF-7/ADR cells were seeded at a density of 5000 cells/well into 96-well culture plates and cultured for 24 h. Cells were then exposed to various concentrations of free DOX, TPP-DOX or HA-ionic-TPP-DOX. Untreated cells were used as blank controls.
After incubation for 48 h, the medium was exchanged with fresh culture medium containing MTT solution (0.5 mg/mL), and incubation was continued at 37 °C for 4 h. Then, the medium was discarded, and DMSO was added to dissolve the formazan crystals formed by living cells. The absorbance was measured at 570 nm with a microplate reader. Reactive oxygen species (ROS) measurements Intracellular ROS production was measured by using the Reactive Oxygen Species Assay Kit (Beyotime Biotech Co, free DOX, TPP-DOX solution or HA-ionic-TPP-DOX for different times (4 h, 12 h, 24 h), the cells were washed twice with PBS and then loaded with DCFH-DA in serum-free medium and incubated at 37 °C for 20 min. The ROS production of the MCF-7/ADR cells was evaluated by using a flow cytometer (FC500MCL, Beckman Coulter, USA).
Measurement of mitochondrial membrane potential
The changes in mitochondrial membrane potential after incubation with free DOX, TPP-DOX solution and HA-ionic-TPPevaluated by a Mitochondrial Membrane Potential Assay Kit with JC-1 (Beyotime Biotech Co, Ltd, Shanghai, China), which -ratio of green and red colors. After incubation for 24 h, the cells were washed and stained with freshly prepared JC-1 at 37 °C for 20 min in the dark, according to the manufacturer's cytometry.
Biodistribution
To investigate the distribution and tumor accumulation ability of the HA-ionic-TPP-DOX, nude female mice (4 weeks old) were administered a subcutaneous injection of 0.1 mL of MCF-7/ADR cancer cell suspension containing 7×10 6 cells. After the tumors had grown to 100 cm 3 , the nude mice were intravenously injected with free DOX, TPP-DOX or HA-ionic-TPP-DOX individually (equivalent DOX, 5 mg/kg). The mice were euthanized at 48 h, and the tumor and organs (heart, liver, spleen, lung, and kidney) were harvested and then imaged with the Maestro TM in vivo imaging system (Cambridge Research and Instrumentation, USA). Meanwhile, for the further determination of DOX localization in tumors was performed according to the guidelines of the Animal Ethics Committee of Zhejiang University (Hangzhou, China).
ation and to investigate the anti-tumor activity of drugs in the xenograft tumor model. Tg(fli1a:eGFP) +/-transgenic zebrafish were raised by standard methods [27] . Fertilization was performed by photo induced spawning over green plants and the observation of anti-tumor effects. In brief, MCF-7/ADR cells were incubated with CM-DiI for 4 min at 37 °C, followed by 15 min at 4 °C, then centrifuged and rinsed to remove unincorporated dye. Then, 200 trypsinized MCF-7/ADR cells were injected into the perivitelline space of dechorionized 48 +/-injection method after the zebrafish had been anaesthetized were maintained at 33°C in Holt-Buffer solution (60 mmol/L NaCl, 2.4 mmol/L NaHCO 3 , 0.9 mmol/L CaCl 2 , 0.67 mmol/L KCl). At 24 h after implantation, 1 nL of free DOX, TPP-DOX or HA-ionic-TPP-DOX was injected into the zebrafish at an equivalent DOX concentration of 1 mg/mL.
thetized with 0.62 mmol/L tricaine and then imaged by a camera (Nikon DS-Ri1)) with a microscope system (Nikon SMZ18) for live imaging. All experimental procedures were conducted in compliance with the directives of the animal welfare committee of Zhejiang University.
In vivo anti-tumor assays in mouse model
Nude female BALB/c mice (4 weeks old) received a subcutaneous injection of 0.1 mL of MCF-7/ADR cancer cell suspension containing 10 7 cells in the right forelimb. When the tumor volume was greater than 50 mm 3 , the tumor-bearing mice were intravenously administered saline, DOX solution, TPP-DOX or HA-ionic-TPP-DOX (equivalent DOX dose, 4 mg/kg) every 2 days. Each group contained six mice. After treatment, the body weight and tumor dimensions were recorded. The tumor volume was calculated using the equation volume=(width 2 ×length)/2. After the end of the experidetected by TUNEL immunohistochemical staining. 
Results and discussion

MASS and NMR spectra
The structural characterization of TPP-DOX and HA-ionic-TPP-DOX were confirmed by 1 H NMR in D 2 O. The signals ranging from 7.5 to 8.0 ppm (d) belong to the protons of the phenyl rings of TPP (Figure 2 A) , and the peaks at 3.2 ppm (c), 2.5 ppm (a) and 1.9 ppm (b) were attributed to the CH2CH 2 P, CH 2 CH 2 COOH and CH 2 CH 2 CH 2 protons of TPP, respectively. For DOX (Figure 2 B) , the peaks at 1.2 ppm (f') and 4.8 ppm (c') were attributed to CH 3 and OCHO in daunosamine, and the peaks at 3.6 ppm (e'), 3.8 ppm (d'), 7.3-7.6 ppm (a', b') belonged to the signals of COCH 2 OH, OCH 3 , and aromatic protons in naphthacenequinone, respectively. For HA, the peaks at 1.9 ppm (n) and 3.2-4.5 ppm (m) correspond to the methyl group (NHCOCH 3 ) and the methenyl group ( Figure  2C ). The peaks for aromatic protons in TPP and DOX were also observed in TPP-DOX 1 H NMR, ranging from 7.0 to 8.0 ppm ( Figure 2D ), which proved the formation of the TPP-DOX conjugate.
The peaks for the aromatic protons (7.0-7.6 ppm) and the methyl group (1.2 ppm) in TPP-DOX, together with the characteristic peaks of HA, were observed in HA-ionic-TPP-DOX 1 H NMR ( Figure 2E ), which proved the conjugation between HA and TPP-DOX. The 13 -matic peaks ranging from 120 to 140 ppm related to TPP and the DOX carbons of aromatic rings ( Figure 2F ), and mass specwith a molecular weight of 874 ( Figure 2G ).
Particle size and TEM analysis of HA-ionic-TPP-DOX
The morphology of HA-ionic-DOX-TPP is spheroidal and monodisperse (PDI=0.096) in water with an average particle size of 257 nm ( Figure 3A ) and a zeta potential of -24.1 mV ( Figure 3B ). Our further study proved that HA-ionic-DOX-TPP could self-assemble into a spherical structure with TPP-DOX as its hydrophobic kernel. In a pH 4.0 dialysis solution, the TPP-DOX electrostatically adhering to HA was replaced by hydrogen ions, resulting in changes to the structure. After losing its hydrophobic TPP-DOX kernel, the spherical structure became hydrophilic long chains intertwining with each other in the water with an average size of 490 nm ( Figure 3C ) and a zeta potential of -21.6 mV ( Figure 3D ). Thus, the structure formed by HA-ionic-TPP-DOX was stable and conducive to intravenous injection. Taking advantage of the long-term systemic circulation of HA and the selectivity of HA for tumors that over-express CD44, TPP-DOX was more effectively transferred into tumor tissues.
In vitro release
The content of TPP-DOX within the HA-ionic-TPP-DOX carrier was measured to be 31.4%, and the solubility of TPP-DOX was 33.87 mg/mL in water and 113.96 mg/mL in chloroform, which suggested that TPP-DOX was amphiphilic. There, it was difficult to entrap physically. Silver nitrate could react with the carboxyl group in HA to produce silver carbonate, and then the bromide ion in TPP-DOX could substitute the silver ion of silver carbonate in HA, leading to the precipitation of silver bromide. Consequently, TPP-DOX was conjugated to the carboxyl group of HA by an ionic bond, which could improve the drug loading and stability of the preparation.
To test the release characteristics of TPP-DOX from the HA nano-complex, dialysis was used [28] . In addition, HA-CDDP formed by ionic interaction has been reported to show a pHsensitive release profile [29] . Therefore, the TPP-DOX release profile was evaluated in phosphate buffer with different pH values: pH 5.0 and 7.4 were used to simulate the endosomal acidic pH and physiological pH, respectively. The HA-ionic-DOX-TPP exhibited faster release at pH 5.0 than at pH 7.4. At 30 h, 91% of TPP-DOX was released at pH 5.0, while only 69% was released at pH 7.4. The pK a value of HA is approximately 3.0 [30] . Both curves showed a burst release of TPP-DOX of up to 25% at pH 5.0 and 34% at pH 7.4 in 0.5 h, reflecting that TPP-DOX could adsorb onto the surface of HA by electrostatic interaction ( Figure 3E ).
Cell uptake of DOX
The cell uptake was measured by flow cytometric analysis (Figure 4) . The cell uptake levels of both TPP-DOX and HAionic-TPP-DOX were significantly higher than that of free TPP results in the avoidance of P-gp recognition and efflux. Furthermore, TPP-DOX showed the highest cell uptake, and the positive charge of TPP-DOX may contribute to its cell 
Cytotoxicity assay in vitro
The cytotoxicity levels of free DOX, TPP-DOX, and HAionic-TPP-DOX were estimated in MCF-7/ADR cells for 48
h. Figure 5 illustrated that all three showed concentrationdependent toxicity. TPP-DOX showed much higher toxicity than free DOX: the IC 50 was far less than the IC 50 toxicity of TPP-DOX was attributed to inducing apoptosis by achieving mitochondrial co-location. In addition, another reason may be that TPP-DOX was positively charged, which could enhance the cell uptake. The IC 50 of HA-ionic-TPP-DOX higher than that of TPP-DOX. It is also reported that the HA nano-complex could prolong circulation in the blood and increase the drug distribution in tumors by the enhanced permeability and retention (EPR) effect [7] .
Assessment of mitochondrial targeting by confocal laser scanning microscopy (CLSM)
The intracellular distribution of DOX was observed by confocal laser scanning microscopy. After 1 h of incubation, little DOX could be observed in MCF-7/ADR cells as a result of the drug-resistance of the tumor cells, while much more TPP-DOX and HA-ionic-TPP-DOX could accumulate in the cells, which is consistent with the cell uptake results mentioned above. However, none of them could be localized in the mitochonthe mitochondria ( Figure 6A ). The confocal fluorescence images of MCF-7/ADR cells incubated with free DOX, TPP-DOX and HA-ionic-TPP-DOX a combination of red and green fluorescence, was used to indicate the co-localization of DOX with the mitochondria. According to the images, both TPP-DOX and HA-ionic-TPP-DOX exhibited punctate distribution, indicating that both TPP-DOX and HA-ionic-TPP-DOX selectively accumulated in the mitochondria of MCF-7/ADR cells. However, after the addibe observed. Free DOX seemed to be localized in the form of dots, perhaps indicating its sequestration in endosomes in the MCF/7 ADR cells, while TPP-DOX and HA-ionic-TPP-DOX were more evenly distributed in the cells. The CSLM images show that the TPP-DOX released from HA-ionic-TPP-DOX might have been able to target mitochondria. Many studies Figure 3 . Characterization of HA-ionic-TPP-DOX. The morphology was observed under a transmission electron microscope (TEM), and the particle size was determined by dynamic light scattering (DLS) (A), together with the zeta potential of HA-ionic-TPP-DOX (B). After HA-ionic-TPP-DOX was dialyzed against excess PBS (pH 4.0) to remove TPP-DOX, its morphology and particle size (C), and zeta potential (D) were observed again. Meanwhile, in vitro release profiles of TPP-DOX from HA-ionic-TPP-DOX in the release media at pH 7.4 or 5.0 (E).
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Acta Pharmacologica Sinica have reported that the surface modification of nanoparticles with TPP or MTS led to a tendency to accumulate in the mitochondria. However, because the size of these nanoparticles ranges from 50 nm to 200 nm [31] [32] [33] , they were too large to target the mitochondria because of obstruction by the components of the cytoplasm. Meanwhile, the molecular weight of TPPmovement in the cytoplasm.
Reactive oxygen species (ROS) measurements
Reactive oxygen species (ROS) play an important role in the induction of apoptosis under both physiological and pathological conditions. Interestingly, mitochondria are both the source and target of ROS, which can be harmful to the cell if produced excessively. Cytochrome c is released from mitochondria and triggers caspase activation. It appears to be largely mediated by direct or indirect ROS action [34] . DOX, TPP-DOX and HA-ionic-TPP-DOX showed no difference in the production of ROS from MCF/ADR cells after exposure for 4 h. However, when the incubation time was increased to 12 h, the ROS production of TPP-DOX was sig-24 h). Compared with that of free DOX, the ROS production of TPP-DOX was twice as high after 12 h, and four times as high after 24 h. HA-ionic much ROS production in cells as free DOX at the 24 h incubation time point (Figure 7 ).
Evaluation of mitochondrial membrane integrity by JC-1 uptake
To test whether the uptake of TPP-DOX and HA-ionic-TPP- 
In vivo distribution
The distributions of DOX solution, TPP-DOX solution and HA-ionic-TPP-DOX group were assessed after intravenous administration ( Figure 9 ). Compared with TPP-DOX and HA-ionic-TPP-DOX groups, little DOX could be observed in the tumor and organs in the DOX group after 24 h intravenous administration, suggesting the rapid elimination and off-target effects of free DOX.
Many tumor cells over-express HA-binding receptors such as CD44, and correspondingly, nano-carriers based on HA, in addition to the enhanced permeability and retention (EPR) A, B) . Furthermore, frozen sections of tumors were harvested, followed by cells in vivo because it offers a rapid and efficient approach for assessing drug effects on human cancer cells at various stages of tumorigenesis, resulting from its in vivo visualization of cell migration and cell mass formation and the interaction between human cancer and zebrafish cells in the transparent animal under microscopic observation [35, 36] . Therefore, MCF-7/ADR cells were labeled with a fluorescent tracking dye (CM-DiI) they proliferated and formed masses primarily in the regions surrounding the intestine, pancreas and liver (1 dpi). After drug treatment for three days (4 dpi), anti-tumor effects were observed in the free DOX, TPP-DOX and HA-ionic-TPP-DOX groups, in contrast to the control group, which had not been treated with the drug. Solid tumors formed in the control and free DOX groups, whereas tumor growth was significantly inhibited in both the TPP-DOX and the HA-ionic-TPP-DOX groups ( Figure 10A ). In addition, HA-ionic-TPP-DOX resulted be due to the targeted delivery and controlled release of HAionic-TPP-DOX ( Figure 10A ). Therefore, HA-ionic-TPP-DOX suppressed tumor growth in the MCF-7/ADR tumor model more effectively than free DOX and TPP-DOX.
Meanwhile, the morphology of the zebrafish was imaged volume, together with body distortion, could be observed in the DOX solution group, indicating cardiotoxicity mediated by DOX. Meanwhile, HA-ionic-TPP-DOX may decrease the side effects, i.e., cardiotoxicity, as no significant difference in the the sustained release of the drug.
Anti-tumor effect in vivo
The tumor volumes and body weights were recorded to evaluate the in vivo ionic-DOX-TPP in nude mice bearing MCF-7/ADR tumors ( Figure 10B,C) . Tumors in mice receiving HA-ionic-DOX-TPP grew to 113.4 mm 3 and were smaller than those in mice that received free DOX solution (180.1 mm 3 ) or TPP-DOX solution (151.1 mm 3 ), while the tumor volume was as large as 239.1 mm 3 in the control group (saline group), demonstrating that HA-ionic-DOX-TPP exhibited a favorable anti-tumor effect in vivo. In addi- tion, the body weights decreased in the free DOX group, while no significant decrease in body weights was observed for other treatments. In addition, immunohistochemical staining was performed by the TUNEL assay to investigate the apoptosis at the tumor site. TUNEL is widely used in the detection In TUNEL immunohistochemistry, the nuclei of the apoptotic cells were stained brown, and the HA-ionic-TPP-DOX group had more apoptotic cells than the DOX group (( Figure 10D) .
Conclusion
In this study, TPP-DOX was conjugated by an ionic bond to the water-soluble polysaccharide HA, which has good biocompatibility and tumor targeting ability, as a framework material to form spherical nanoparticles by self-assembly. HA on the surface of the nanoparticle prolonged the circulation time in the blood and achieved tumor targeting by the CD44 receptor while bearing TPP-DOX in the core hydrophobic region. The suitable particle size and surface negative charge of HA-ionicby the EPR effect. The small molecule TPP-DOX exhibited excellent ability to target the mitochondria, compared with -ity of HA-ionic-TPP-DOX was slightly better than that of free DOX, and it significantly inhibited tumor growth and profree DOX, suggesting potential prospects for in vivo use in the future.
